Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants
Study sponsor: Rhythm Pharmaceuticals, Inc. · RYTM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2013-09-28Actual
Enrollment · participants74Actual
Source updated2023-08-14Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.